Cooper Companies Stock Plunges After Strategic Review Ends Without CooperSurgical Sale

Cooper Companies saw its shares tumble 15.3% in extended trading to $53.80 after the medical-device maker released fiscal third-quarter 2026 results and, at the same time, said its strategic review had concluded with a decision to hold on to CooperSurgical, its women’s health and fertility division, rather than divest it. The absence of a sale was the primary catalyst behind the after-hours drop, given that Wall Street had been pricing in a possible disposal since the review was officially initiated in December 2025 amid pressure from activist investors.

After evaluating expressions of interest from multiple parties, the board said it had unanimously determined that none of the offers adequately captured CooperSurgical’s worth, pointing to two factors that depressed bids: a new rival entering the non-hormonal IUD segment and the financial drag from a recently settled fertility-related lawsuit. On results, non-GAAP diluted EPS landed at $1.15, marginally above the $1.12 analyst consensus, while revenue edged up just 1% year over year to $1.066 billion, essentially matching forecasts. CEO Al White warned that U.S. distributors trimming inventory at CooperVision had hurt fiscal Q3 and would continue to weigh on fiscal Q4. The company guided Q4 non-GAAP EPS to $1.05–$1.09 and full-year revenue to $4.229–$4.252 billion, implying only 2–3% organic growth, a projection that disappointed the market. Although the board raised its share-repurchase authorization to $3 billion from $2 billion, the increased capital-return capacity failed to compensate for the strategic-review letdown.

Broader U.S. equities offered little shelter: the S&P 500 finished essentially flat at +0.0%, the Dow Jones Industrial Average rose a mere 0.1%, and the Nasdaq was unchanged for the session. That backdrop underscores the after-hours slide was solely a reaction to company-specific developments, with no notable central-bank statements or economic releases moving the medical-device space during the regular session.

Collectively, the failed sales process, the fresh competitor in the IUD arena, CooperVision's cautious fourth-quarter inventory comments, and full-year guidance that came in below expectations formed a perfect storm of bearish catalysts in extended trading. The shares were pushed toward their lowest point in recent months, erasing the run-up that had been built before the earnings release.

This article was produced with AI assistance and reviewed by an editor. For additional information, refer to our Terms and Conditions.